Eloxx Pharmaceuticals, Inc. (ELOX)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Feb 27, 2026, 4:00 PM EST
0.00%
Market Cap 330.00
Revenue (ttm) n/a
Net Income (ttm) -20.48M
Shares Out 3.30M
EPS (ttm) -8.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 343
Average Volume 3,295
Open 0.0001
Previous Close 0.0001
Day's Range 0.0001 - 0.0001
52-Week Range n/a
Beta -171,373.26
RSI 47.90
Earnings Date n/a

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of RNA-modulating drugs in the United States. The company develops ELX-02, which is in phase II clinical trial for the treatment of nonsense mutation alport syndrome; ZKN013, which is in investigation phase for the treatment of nonsense mutation recessive dystrophic and junctional epidermolysis bullosa; and ZKN013, which is in investigation phase for the treatment of nonsense mutation familial adenomatous polyposis. It also offers platform techno... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 18
Stock Exchange OTCMKTS
Ticker Symbol ELOX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.